Your SlideShare is downloading. ×
Prodution of Biopharmaceuticals : An Overview - PowerPoint ...
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Prodution of Biopharmaceuticals : An Overview - PowerPoint ...

9,143
views

Published on


4 Comments
4 Likes
Statistics
Notes
  • very informative and useful.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • very informative and comprehensive
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • its really a useful presentation
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • what a presentation!!!! wow.... its so amazing
    thank you so much
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
9,143
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
522
Comments
4
Likes
4
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Production of Biopharmaceuticals – An Overview K.R.S.Sambasiva Rao Department of Biotechnology Acharya Nagarjuna University
  • 2. What are Biopharmaceuticals Biologically significant compounds like hormones and proteins useful for treatment of variety of human health disorders, usually called as Biopharmaceuticals or Biotherapeutics or Biologicals, usually obtained from biological source and produced through industrial biotechnology
  • 3. Microorganisms as tools for production of various Biotherapeutics • From genes to processes • Gene resources – Gene diversity – Methods of gene discovery • Expression of genes and production of gene products • Use of organisms and enzymes as catalysts • Environmental processes • Fermentation processes • Biotransformations
  • 4. From Genes to Processes Gene discovery Cloning/expression Production and scale-up Engineering the catalyst Application
  • 5. • Insulin- hormone which lowers blood sugar; used by diabetics • Interferon- class of cytokines effective vs viral infections • Factor VIII- blood protein necessary for clotting; missing in hemophiliacs • Streptokinin - bacterial enzyme to dissolve blood clots in coronary arteries • Beta endorphins- pain suppressors Important Biotherapeutics
  • 6. Production of Biotherapeutics Microbes as Factories for Biotherapeutics
  • 7. The technology is relatively simpler compared with the other systems In Vitro maintenance does not require special components Their unicellular nature Their genomes are simpler Their ecological distribution is very diverse Why we have to choose this technology
  • 8. Potential of a Microbes Microorganisms are capable of growing on a wide range of substrates and can produce a remarkable spectrum of products
  • 9. Which Microbes are useful Several species belonging to the following categories of microorganisms are useful PROKARYOTIC Unicellular: Bacteria, Cyanobacteria Multicellular: Cyanobacter EUKARYOTIC Unicellular: Yeasts, Algae Multicellular: Fungi, Algae
  • 10. Some potential microbes used in Microbial Technology
  • 11. Bacillus Sp. Actinimycetes Sp.
  • 12. Eschericia coli
  • 13. Saccaromyces cerevisiae (Yeast)
  • 14. Coprinus cinereus
  • 15. Biologicals vs Conventional Drugs Biologicals • Protein or carbohydrate based product • Extracted from living organism • Complex physicochemical structure • Less well-defined  Macromolecule (> 500 kd)  Tertiary structure  Location, extent and type of glycosylation • Heat- & Shear- sensitive Conventional Drugs • Synthetic, organic compounds • Defined structure, physical & chemical characteristics  Chemical synthesis  Micromolecules  Stable
  • 16. More than 30 recombinant therapeutics have been approved globally for commercial use and several are on the way • In India, 12-15 of these are presently being marketed. Many of these are being imported (excepting few like Hepatitis B vaccine, Insulin etc.) and consumed and now several are underway for indigenous production • Globally approved recombinant therapeutics are broadly categorized into blood factors, hormones, growth factors, interferons, interleukins, vaccines and other miscellaneous therapeutic products
  • 17. Some approved Therapeutics The products of rDNA technology • Hormones – Growth hormone, Insulin, Calcitonin, FSH • Cytokines – Interferons (Interleukins), EPO, CSF, Neurotrophic factors • Clotting factors – Factor VIII, Factor IX • Vaccines – Hepatitis B, acellular pertussis vaccine (Bordatella pertussis, whooping cough) • Monoclonal antibodies
  • 18. Human Insulin Streptokinase Erythropoietin Hepatitis B vaccine Human growth hormone Human interleukin .  Granulocyte macrophage colony stimulating factor  Alpha-interferon,  Gamma-Interferon,  Blood factor VIII  Follicle stimulating hormone  Granulocyte colony stimulating factor (GCSF), Therapeutic products approved in India Shantha Biotechnies Pvt. Ltd., Bharat Biotech International, Wockhardt, Reddy Labs and Panacea Biotech, Biological E limited, Virchow Biotechniques etc. have initiated the production of several of these therapeutics and some growth factors in our country
  • 19. The commercial production of recombinant Biologicals and therapeutics now became an important area in global industralization The process developed in production of therapeutics has to be taken to industrial scale for implementing these developed process in industrial scale and to get viable industrial production of these therapeutics or biologicals mainly through Fermentation technology Commercial production of Therapeutics
  • 20. And any Fermentation process should go for scale-up from laboratory scale to Industrial level Through Pilot scale Fermentors
  • 21. Pilot scale Fermenter
  • 22. Industrial Scale up process
  • 23. Marlow Foods, UK World largest (50 m tall and 155,000 litre capacity) airlift fermenter (1994) Production of Quorn™ myco-protein
  • 24. Commercial Production of Some important Biotherapeutics
  • 25. • Insulin is an important hormone which regulates sugar metabolism • An inability to produce insulin results in a form of diabetes, this disease can be treated by daily injections of insulin • Historically, insulin from pigs or cows is used, but known to produce immune reactions in some patients • Challenge: how to make human insulin to be used as a drug in cell systems or microbes? Insulin - first recombinant protein to be produced
  • 26. – Idea: take the gene of human insulin, clone into a plasmid, introduce the plasmid into E. coli or cells, and use them E.coli as “Biological Factory” for insulin production – Amino acid sequence produced insulin (Contains 51 amino acids) and is identical to that of the “natural human protein” and it will not cause any immune reactions – Much more economical than attempts to produce insulin by chemical synthesis – So, how to do this? Recombinant Insulin overcome many problems
  • 27. Strategy for insulin production
  • 28. Insulin crystals from the purification process
  • 29. Owen Mumford Ltd., UK
  • 30. Human growth hormone (hGH, or Somatotropin) • Secreted by the pituitary gland, and is responsible for normal body growth and development, by stimulating protein production in muscle cells, energy release from the breakdown of fats and stimulates the development of bones • These processes together are responsible for longitudinal growth. Inadequate production of GH results in short stature, defined as a below normal height for a given age
  • 31. • In children and adolescents, the rate of growth in height is primarily determined by the rate at which endogenous GH is secreted • The growth spurt during puberty is caused by increased secretion of GH • Under normal conditions, GH secretion and growth rate remain increased until final height is reached, after which GH secretion is reduced to a steady state
  • 32. Growth Hormone: 191 amino acids, single chain Structure of human Growth hormone Teritiary structure Primary structure Hormone binding to receptors
  • 33. Production of recombinant GH Isolating and constructing hGH cDNAs Constructing expression cassette with hGH cDNAs inserts Cultivating the recombinant clones in small scale flask/bioreactor Producing the hGH in pilot scale bioreactors Developing large scale purification procedure and process chromatography optimization (Affinity chromatography)
  • 34. Production of hGH • Purification of recombinant human growth hormone (rhGH) from Chinese hamster ovary (CHO) cell culture supernatant by Gradiflow large-scale electrophoresis is described. Production of rhGH in using E. coli as an alternative for using CHO cells, with the advantage that rhGH is secreted into protein- free production media, facilitating a more simple purification and avoiding resolubilization of inclusion bodies and protein refolding. proteins
  • 35. Strategy for production of growth hormone
  • 36. Erythropoietin • Human Eryhtopoietin is produced in kidney • A glycoprotein, acts on the bone marrow to increase the production of red and white blood cells. Stimuli such as bleeding or moving to high altitudes (where oxygen is scarce) trigger the release of erythropoietin • Known as EPO, MW 30400 Kda, 165 amino acids in human (192 Mouse) • Has been widely used in AIDS for development of immunity
  • 37. Kidney is the principal production site of Erythropoietin Bones like Femur, Tibia, Vertebra, Sternum, Rib produce most RBC and WBC under the influence of EPO
  • 38. When EPO is produced When RBC count comes down (Oxygen level decreases) in the blood It will result in Kidney cells specifically sense the oxygen deficit in the blood and start producing Erythropoietin
  • 39. Structure of EPO ( A Glycoprotein of 165 amino acids)
  • 40. EPO also has therapeutic Abuses • Used in sports to improve endurance • Now detected from naturally occurring EPO by protein markers produced during post injection phase
  • 41. Production of recombinant Erythropoietin • Isolating and constructing human EPO cDNAs • Subjecting the cDNA to PCR using primers based on the published sequence • The PCR products will be cloned into vector for the purpose of propagation and subsequently engineered into appropriate expression vectors
  • 42. Genomic DNA, cDNA and manufactured DNA sequences coding for part or all the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable prokaryotic or eukaryotic host cells such as bacteria, yeast or vertebrate cells in culture Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g. the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins will be tested Production process….
  • 43. Vial Flask/ Roller Bottle (Cells) Spinner Bottle / Bio-reactor Purification Production Final Bulk EPO concentrate Flow Chart of Production Process
  • 44. TPA Has Been Developed As A Drug By Genentech • The biotechnology company Genentech has cloned human t-PA for use in treating unwanted or life threatening blood clots • Activase (Alterplase recombinant) is the trade name of Genentech’s t-PA • Activase is useful in treating heart attacks and strokes when administered within 5 hours of thrombosis formation or embolism lodging in the heart or brain • The FDA approval in 1987 and medical use of Activase has a very interesting history
  • 45. TPA mode of action Damaged Tissues t-PA t-PA t-PA Clot Dissolution Fibrin Breakdown Activation PlasminPlasminogen Urokinase From the Kidneys Streptokinase From Bacteria
  • 46. Vaccines Vaccines effective against many viral infections and diseases require the cultivation and mass production of the virus followed by its attenuation The drawback in this is that virus requires a living medium to replicate and multiply. Rather than the traditional concept- “Sacrifice one life to save many”, Animal cell culture can be employed to mass produce the virus Passively, Animal cell culture can be employed to reduce the virulence of particular virus strains by cultivating them on cells other than target cells, in which the virus infection followed by repeated passaging will be performed The cell-culture process for vaccines offers high potential as an alternative method to egg-based production. Cell culture has the capability to offer a predictable, rapid and responsive method for production of well-tolerated and effective vaccines, with low levels of adverse events similar to egg-based vaccines Cell-culture materials can be stored, so the production process can be initiated at any time. In addition, production can be scaled up in response to increased vaccine demand
  • 47. Recombinant Hepatitis vaccine • The hepatitis B virus (HBV) vaccine – Originally based on the surface antigen purified from the blood of chronically infected individuals. – Due to safety concerns, the HBV vaccine became the first to be produced using recombinant DNA technology (1986) – Produced in bakers’ yeast (Saccharomyces cerevisiae Electron micrograph of the hepatitis B virus
  • 48. Recombinant Hepatitis B Vaccine • One of the most recent developments is the production of a vaccine against hepatitis B using genetically modified yeast cells • Hepatitis B is a viral infection which attacks the cells of the liver. It can be very serious, causing chronic liver failure, liver cancer and death • Hepatitis B can be prevented by a vaccination, and in countries like India where it is relatively common
  • 49. Problems With The Early Traditional vaccine • For many years the vaccine was produced by growing the live virus in animals and then inactivating it by chemical treatment • This led to the risk of infection during the manufacture, and in the delivery of the vaccine, as well as raising animal rights issues
  • 50. • The Gene coding for the HsbAg is isolated and cloned into a Vector Under the control of a strong promoter • The cloned gene is transferred to the Yeast Expression system • The gene is allowed to express in the yeast and the recombinant protein product of the Hepatitis is obtained • The protein is later purified and used to for vaccination
  • 51. Gene encoding the 226 amino acid hepatitis B surface antigen (HBsAg), was cloned into yeast) The 5' end of the HBsAg gene was replaced with another DNA segment so as to optimize synthesis in yeast High-cell-density fermentations of laboratory strains of yeast have been developed for the production of HBsAg The HBsAg (lipoprotein particle) in cell lysates has been purified to obtain homogeneity
  • 52. • to respond to a human influenza pandemic. • to respond to a human influenza pandemic. Vaccine Production at industry level
  • 53. Some viral vaccines currently available for human and veterinary use
  • 54. Aspartame (L-phenylalanyl-L-aspartyl- methyl ester) is a low-calorie artificial sweetener It can be synthesised biocatalytically by peptide synthesis using a thermostable protease – Thermolysin® from the facultative thermophile, Bacillus thermoproteolyticus Food Additive - Aspartame
  • 55. Production of Nicotinamide Nicotinamide is an essential vitamin, and is widely used in the health-food and animal food-and-feed industries. Biological production, using the same Rhodococcus biocatalyst as for acrylamide production, operates at about 5kT p.a. Nicotinamide Rhodococcus whole cell biocatalyst 3-cyanopyridine
  • 56. Acrylamide is one of the most important chemical commodities, being in great demand (200 000 tons per year worldwide) as a starting material for the production of various polymers. Nicotinamide is a Vitamin that can also be synthesized in the same biological process Value added products
  • 57. • Acrylamide – Absorbent polymers – Flocculants – Construction material • Nicotinic acid – Animal feed supplement – Human Health food supplement Uses
  • 58. Effects of alkaloids on humans • High biological activity • Produce varying degrees of physiological and psychological responses - largely by interfering with neurotransmitters – others interfere with membrane transport, protein synthesis or other processes • In large doses - highly toxic - fatal • In small doses, many have therapeutic value – muscle relaxants, tranquilizers, pain killers, mind altering drugs, chemotherapy Production of Alkaloids from Plants
  • 59. Stem Cells: Elixir for the 21st Century? Alzheimer’s Disease Parkinson’s Disease Various Leukemias Hodgkin’s Lymphoma Non-Hodgkin’s Lymphomas Immune Deficiency Disease Liver Failure Heart Disease Diabetes Stroke Multiple Sclerosis Huntington’s Disease Osteoarthritis Rheumatoid Arthritis Coeliac Disease Crohn’s Disease Lupus Erythematosus Periodontal Disease Sickle Cell Anaemia Thalassemia Psoriasis Deafness Blindness Osteoporosis Spinal Injuries Burns Blackfan Diamond Anaemia Fanconi Anaemia
  • 60. Demand for large scale manufacturing of Health care products At present, the majority of therapeutic biopharmaceuticals has been produced using animal cell technology and include proteins used for the • treatment of cardiovascular diseases (tissue plasminogen activator: tPA, reteplase) • cystic fibrosis (DNases) • anemia (erythropoietin: EPO) • haemophilia (coagulation factors VIII and IX) • cancer and viral infections (interferons and interleukins), multiple sclerosis (interferon-beta2) and • dwarfism (human growth hormone: hGH)
  • 61. Health Care engaged by our group
  • 62. Staphylokinse • It is a upcoming 3rd generation thrombolytic agent. It can dissolve the blood clot effectively compared to the existing agents
  • 63. • The current generation of thrombolytic agents constitute t-PA, Urokinase, Streptokinase etc. • Thrombolysins derived from eukaryotic cells (t-PA and Urokinase) can efficiently degrade the clots. But, they cannot meet the clinical requirements of the day because they pose greater problems in commercial production due to their large molecular size and expression incompatibilities • Streptokinase having a problem of systemic hemorrhage
  • 64. In contrast, the Staphylokinase has surpassed these incompatibilities and has proved to be a better alternative Major bottlenecks in clot dissolution by Therapeutics • Reocclusion • Half life • Antigenicity • Production cost
  • 65. SAK as a better alternative  Simple protein  Small size  Less antigenic than the SK  High Fibrin specificity  New chimera with SAK was developed (a patent was filed)
  • 66. Streptokinase • Widely using thrombolytic agent • Cheaper than all • Not Clot specific, can lead to Systemic hemorrhage • Even it is dangerous, it is very popular because of its low cost • Research is going on to avoid the pitfalls of the agent • Our group is engaged in developing a new fusion protein with SK, a patent is going to be filed
  • 67. Synthetic Antimicrobial Peptides As all the bacterial strains developing resistance to the conventional antibiotics, an attempt was made by our group to develop a broad spectrum synthetic antimicrobial peptide
  • 68. Biotherapeutics are delicate drugs • Much larger and more complex than traditional pharmaceuticals • Composed of unstable proteins with a precise structure • Easily damaged by unfavorable temperature history during storage
  • 69. Even insulin has temperature problems • Insulin is a very temperature stable biotherapeutic • A graph of storage life vs temperature shows a “saw tooth” peak • The product dies at both temperature extremes Insulin Shelf-life 0.1 1 10 100 1000 -20 0 20 40 60 Temperature (C) Months
  • 70. Effect of temperature storage extremes < 0 o C • Freezing • Protein denaturation • Formation of aggregates • Loss of functional activity • Formation of potentially hazardous immunogenic byproducts > 8o C • Chemical side reactions • Protein denaturation • Formation of aggregates • Loss of functional activity • Formation of potentially hazardous immunogenic byproducts
  • 71. Smart packaging vs dumb packaging • Smart packaging can guard against human errors in handling, and accidental temperature abuse. • Is traditional dumb packaging simply a relic from an earlier era? Does it pass modern failure modes analysis?